NCT05286437View on ClinicalTrials.gov

Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Interventions
DRUG

Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole

Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.

Trial Locations (1)

169610

RECRUITING

National Cancer Centre Singapore, Singapore

All Listed Sponsors
collaborator

MSD Pharma (Singapore) Pte Ltd

UNKNOWN

lead

National Cancer Centre, Singapore

OTHER